Aspen Pharmacare’s CEO, Stephen Saad, has celebrated the company’s new licensing agreement to enter the rapidly expanding GLP-1 agonist market. He said this milestone marks a “significant coup” for the company, enabling it to prepare for the market by 2026 and capitalise on the anticipated demand for diabetes and obesity treatment solutions.
The global GLP-1 market, driven by increased demand for diabetes and obesity treatments, is projected to grow to $142bn (R2.5 trillion) by 2030. Key GLP-1 drugs, including Ozempic, Wegovy, and Rybelsus, are expected to dominate the market as patents begin expiring in 2026, opening doors for Aspen’s entry.
Aspen to manufacture and supply complex GLP-1 delivery systems
Aspen’s agreement grants intellectual property rights for manufacturing and commercialisation, particularly in multi-dose pens and auto-injectors. These complex delivery systems promise to enhance patient accessibility, meet high demand, and position Aspen as a key supplier in select markets.
With established sterile manufacturing facilities in South Africa and France, Aspen is poised to ramp up production for GLP-1 products and address a significant gap in global manufacturing capacity. The company’s experience in sterile injectables aligns well with the needs of the market, positioning it for strong future performance.
Projected financial growth and market impact
Aspen anticipates R2.45bn in incremental EBITDA over the 2025-2026 financial years, driven by product demand. While regulatory approvals are still pending, this new venture will benefit its commercial and manufacturing segments, supported by recent acquisitions, including Sandoz China and Eli Lilly products in Latin America and South Africa.
According to GlobalData, the GLP-1 agonist sector is expected to surpass other pharmaceutical markets, outpacing even PD-1 antagonist drugs by 2029. This trend reflects a shift in focus towards metabolic disorders as industry leaders drive innovation in diabetes and obesity treatment options.